BANGKOK (The Nation/ANN): Mahidol University (MU) is developing versions of its new dust allergy vaccine that patients will be able to use at home, reducing their risk of being exposed to Covid-19.
MU’s Faculty of Medicine Siriraj Hospital earlier announced it had successfully developed South-east Asia’s first dust allergy vaccine, which has been registered with the Food and Drug Administration (FDA) and is protecting patients who are allergic to dust mites.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
